[{"NetIncomeLoss_1_Q1_USD":-49484000.0,"FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_0_Q1_USD":1000000.0,"DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_0_Q1_USD":28999000.0,"CommitmentsAndContingencies_0_Q1_USD":null,"AccruedLiabilitiesCurrent_0_Q1_USD":30316000.0,"RestrictedCashCurrent_0_Q1_USD":210000.0,"InventoryFinishedGoodsNetOfReserves_0_Q1_USD":2189000.0,"PaymentsToAcquireShortTermInvestments_1_Q1_USD":74362000.0,"AccumulatedOtherComprehensiveIncomeLossNetOfTax_0_Q1_USD":-21000.0,"WeightedAverageNumberOfShareOutstandingBasicAndDiluted_1_Q1_shares":68269486.0,"NetCashProvidedByUsedInInvestingActivities_1_Q1_USD":44834000.0,"DividendsCommonStockCash_1_Q1_USD":0.0,"IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_1_Q1_USD":0.0,"AssetsCurrent_0_Q1_USD":275564000.0,"CashCollateralForBorrowedSecurities_0_Q1_USD":210000.0,"AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_1_Q1_shares":10939018.0,"Assets_0_Q1_USD":311158000.0,"ShareBasedCompensation_1_Q1_USD":7126000.0,"OperatingLeaseRightOfUseAsset_0_Q1_USD":5982000.0,"Depreciation_1_Q1_USD":290000.0,"IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_1_Q1_USD":-408000.0,"GeneralAndAdministrativeExpense_1_Q1_USD":20600000.0,"OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_1_Q1_USD":13000.0,"ShortTermInvestments_0_Q1_USD":144169000.0,"IncreaseDecreaseInOtherNoncurrentAssets_1_Q1_USD":231000.0,"ResearchAndDevelopmentExpense_1_Q1_USD":28683000.0,"FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_0_Q1_USD":1000000.0,"IncreaseDecreaseInAccruedLiabilities_1_Q1_USD":1079000.0,"ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_1_Q1_pure":0.7726,"IncomeTaxExpenseBenefit_1_Q1_USD":210000.0,"NetCashProvidedByUsedInFinancingActivities_1_Q1_USD":1106000.0,"DepreciationAndAmortization_1_Q1_USD":312000.0,"FairValueAssetsLevel2ToLevel1TransfersAmount_0_Q1_USD":0.0,"ComprehensiveIncomeNetOfTax_1_Q1_USD":-49471000.0,"IncreaseDecreaseInAccountsPayable_1_Q1_USD":72000.0,"ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_1_Q1_pure":0.0098,"OtherAssetsNoncurrent_0_Q1_USD":5797000.0,"CashAndCashEquivalentsAtCarryingValue_0_Q1_USD":119856000.0,"OperatingLeaseLiabilityNoncurrent_0_Q1_USD":4200000.0,"Liabilities_0_Q1_USD":40462000.0,"IncreaseDecreaseInOtherNoncurrentLiabilities_1_Q1_USD":4000.0,"CashCashEquivalentsAndShortTermInvestments_0_Q1_USD":264025000.0,"FairValueAssetsLevel1ToLevel2TransfersAmount_0_Q1_USD":0.0,"OperatingIncomeLoss_1_Q1_USD":-49283000.0,"InventoryNet_0_Q1_USD":2189000.0,"OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_1_Q1_USD":13000.0,"OperatingLossCarryforwards_0_Q1_USD":0.0,"IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_1_Q1_USD":-49274000.0,"AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_1_Q1_USD":7126000.0,"NetCashProvidedByUsedInOperatingActivities_1_Q1_USD":-40122000.0,"LiabilitiesCurrent_0_Q1_USD":35453000.0,"CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_1_Q1_USD":5818000.0,"AccountsPayableCurrent_0_Q1_USD":2763000.0,"AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_0_Q1_USD":5020000.0,"CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0_Q1_USD":120066000.0,"ProceedsFromStockOptionsExercised_1_Q1_USD":1106000.0,"OtherAccruedLiabilitiesCurrent_0_Q1_USD":291000.0,"EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_1_Q1_pure":0.0,"AdditionalPaidInCapital_0_Q1_USD":837656000.0,"PaymentsToAcquireIntangibleAssets_1_Q1_USD":20000000.0,"FiniteLivedIntangibleAssetsNet_0_Q1_USD":20000000.0,"FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_0_Q1_USD":14250000.0,"PropertyPlantAndEquipmentNet_0_Q1_USD":3815000.0,"PrepaidExpenseAndOtherAssetsCurrent_0_Q1_USD":9140000.0,"FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_0_Q1_USD":1000000.0,"FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_0_Q1_USD":1000000.0,"RetainedEarningsAccumulatedDeficit_0_Q1_USD":-566957000.0,"InvestmentIncomeInterest_1_Q1_USD":9000.0,"FiniteLivedIntangibleAssetsGross_0_Q1_USD":20000000.0,"DeferredIncomeTaxExpenseBenefit_1_Q1_USD":10000.0,"LiabilitiesAndStockholdersEquity_0_Q1_USD":311158000.0,"EmployeeRelatedLiabilitiesCurrent_0_Q1_USD":7130000.0,"AllocatedShareBasedCompensationExpense_1_Q1_USD":7126000.0,"PropertyPlantAndEquipmentGross_0_Q1_USD":8835000.0,"OperatingLeaseLiabilityCurrent_0_Q1_USD":2374000.0,"FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_0_Q1_USD":750000.0,"OperatingExpenses_1_Q1_USD":49283000.0,"EarningsPerShareBasicAndDiluted_1_Q1_USD":-0.72,"ProfitLoss_1_Q1_USD":-49484000.0,"OtherLiabilitiesNoncurrent_0_Q1_USD":809000.0,"StockholdersEquity_0_Q1_USD":270696000.0,"PaymentsToAcquirePropertyPlantAndEquipment_1_Q1_USD":54000.0,"FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_0_Q1_USD":1000000.0,"AccretionAmortizationOfDiscountsAndPremiumsInvestments_1_Q1_USD":-410000.0,"ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments_1_Q1_USD":139250000.0,"AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition_1_Q1_USD":1106000.0,"AccruedProfessionalFeesCurrent_0_Q1_USD":2857000.0,"PurchaseCommitmentRemainingMinimumAmountCommitted_0_Q1_USD":17091000.0,"Ticker":"KNSA","CIK":"1730430","name":"KINIKSA PHARMACEUTICALS, LTD.","OfficialName":"Kiniksa Pharmaceuticals Ltd. Class A Common Stock","form":"10-Q","period":"20210331","fy":"2021.0","fp":"Q1","qtrs":"1","uom":"USD","footnote":"nan","Market Cap":"764985918.0","Country":"United States","Sector":"Health Care","Industry":"Biotechnology: Pharmaceutical Preparations","Market":"NASDAQ","SP500":"nan","filed":"20210506"}]